Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047073 · ClinicalTrials.gov registry record · Phase 1
Sirolimus in Treating Patients With Glioblastoma Multiforme
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00047073: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by Jonsson Comprehensive Cancer Center.
NCT00047073 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 13 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00047073, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Chemotherapy drugs such as sirolimus use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase I/II trial to study the effectiveness of sirolimus in treating patients who have glioblastoma multiforme that did not respond to previous radiation therapy.
Conditions Studied
Interventions
- PROCEDURE Surgery
- DRUG Rapamycin
- PROCEDURE Supportive Care
Study Locations (1)
California
- Jonsson Comprehensive Cancer Center at UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2002-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
What the finished NCT00047073 record still lists
NCT00047073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions - of which Surgery is the first listed.
NCT00047073 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00047073 about?
NCT00047073 is a clinical study titled "Sirolimus in Treating Patients With Glioblastoma Multiforme". RATIONALE: Chemotherapy drugs such as sirolimus use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase I/II trial to study the effectiveness of sirolimu...
What is the current status of trial NCT00047073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2002-07. Estimated completion is 2007-10.
What conditions does trial NCT00047073 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00047073?
The interventions under investigation include: Surgery (PROCEDURE), Rapamycin (DRUG), Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT00047073?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047073 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00047073's enrollment target sits among peer trials
13 41st of 45 higher than 5 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia